Dantrolene rescues aberrant N-terminus intersubunit interactions in mutant pro-arrhythmic cardiac ryanodine receptors

Monika Seidel1, N Lowri Thomas1, Alan J Williams1

  • 1Wales Heart Research Institute, Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff CF14 4XN, UK.

Cardiovascular Research
|November 21, 2014
PubMed
Abstract

Insights

A mutation in the cardiac ryanodine receptor (RyR2) disrupts its N-terminus self-association, leading to arrhythmias. Dantrolene treatment restores normal RyR2 channel function, offering a potential therapeutic strategy for inherited cardiac disease.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Ion Channel Physiology

Background:

  • The ryanodine receptor (RyR2) is critical for cardiac excitation-contraction coupling.
  • Dysfunctional RyR2 channels are implicated in arrhythmias and sudden cardiac death.
  • Inherited arrhythmogenic cardiac diseases often stem from RyR2 dysfunction.

Purpose of the Study:

  • To investigate the molecular mechanisms underlying RyR2 dysfunction in inherited arrhythmogenic cardiac disease.
  • To elucidate the role of the RyR2 N-terminus in channel function and oligomerization.
  • To explore the therapeutic potential of dantrolene in restoring RyR2 channel function.

Main Methods:

  • Yeast two-hybrid assays to assess RyR2 N-terminus self-interaction.
  • Co-immunoprecipitation and chemical cross-linking to confirm protein interactions.
  • Sucrose density gradient centrifugation to evaluate RyR2 tetramerization.
  • [3H]Ryanodine binding assays for Ca2+ activation sensitivity.
  • Calcium imaging in RyR2-expressing cells to assess Ca2+ transients and store content.

Main Results:

  • The L433P mutation significantly impairs RyR2 N-terminus self-association and tetramerization.
  • RyR2(L433P) channels exhibit altered Ca2+ sensitivity, prolonged Ca2+ transients, and reduced Ca2+ store content.
  • Dantrolene treatment effectively reverses the L433P mutation-induced functional deficits.
  • Restoration of normal RyR2 channel function was observed following dantrolene administration.

Conclusions:

  • The RyR2 N-terminus is a key structural element for functional RyR2 oligomerization.
  • Defective N-terminus self-association is a molecular mechanism for RyR2 channel deregulation in inherited cardiac disease.
  • Dantrolene may exert its therapeutic effects by restoring normal RyR2 N-terminal intersubunit interactions.

Related Concept Videos

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
1.5K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
3.1K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
814
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.4K
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
650